circulating Tumour DNA
Development of circulating tumour DNA analysis for gastrointestinal cancers
... detect tumour heterogeneity. Recently, the analysis of circulating tumour DNA (ctDNA) using polymerase chain reaction- based or NGS- based methods has demonstrated the capability to detect ...
9
Science in Focus: Circulating Tumour DNA as a Liquid Biopsy.
... plasma DNA. The fraction of plasma DNA derived from tumour varies greatly between patients with cancer, but is often as low as 1% or ...This circulating tumour DNA (ctDNA) can be ...
6
Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags
... Sensitive and accurate identification of specific DNA mutations can influence clinical decisions. However accurate diagnosis from limiting samples such as circulating tumour DNA (ctDNA) is ...
8
Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.
... sequence-specific DNA at extremely low concentrations within clinically appropriate time and cost ...for circulating tumour DNA (ctDNA) to emerge as a viable cancer ...
21
Circulating tumour DNA for monitoring colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection
... of DNA are associ- ated with CRC development, and a number of studies show that tumour-derived DNA can be detected in the cell-free fraction of blood (circulating tumour DNA, ...
11
The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review
... [4]. Circulating cell free DNA produced from cancers is known as circulating tumour DNA (ctDNA), and represents a subset of the circulating DNA (cfDNA) normally present at ...
17
Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA
... instructions, DNA samples were mixed with 2× Taq- Man® Gene Expression Master Mix (Life Technology, 4369016), 20× GE Sample Loading Reagent (Fluidigm, 85000746) and 20× gene-specific ...
14
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
... We investigated the genetics of breast cancers progressing on first line AI, with eTAm-Seq deep sequencing of ctDNA from progression plasma samples. Consistent with other studies (5) (12) (13), TP53 (36.1% (13/36)), ESR1 ...
18
Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.
... decade later, cDNA and ctDNA levels in plasma were shown to be higher in bladder cancer patients than in healthy controls [39,40]. Then, there followed a hiatus in publications on ctDNA in MIBC until Bettegowda et al.’s ...
14
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
... in tumour tissue only and 7 (4%) in plasma ...in tumour tissue and patient outcome assessed by presence/absence of these ...experienced tumour recurrence following curative treatment, 2 were alive ...
9
Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma.
... prior targeted tumour tissue sequencing in cases with detectable ctDNA, as well as finding 52.. additional changes.[r] ...
28
Vol 28, No 3 (2015)
... cell-free circulating tumour DNA and circulating tumour cells would allow an early detection of resistance and relapse to therapies, as well as changes in the overall clonal composition ...
7
Cell-free DNA in non-small cell lung cancer
... foetal DNA in the circulation of expectant mothers as a form of non-invasive prenatal (NIP) testing (3, ...that circulating cfDNA exists at steady- state levels and increases, sometimes dramatically, with ...
7
Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients
... Even though new developments in clinical research on breast cancer (BC) have provided clinicians with a set of important diagnostic tools, there is still an urgent need for further, more sensitive staging techniques. Re- ...
5
Recent advances in the biology of human circulating tumour cells and metastasis
... primary tumour, while little or no informa- tion is available from the various metastatic lesions that are present at that speci fi c ...primary tumour, an approach that has led to no ...primary ...
9
Gene expression of circulating tumour cells in breast cancer patients
... Comparisons of controls and BC patient groups re- vealed an increased frequency of ga733.3 (8/63 vs. 1/14), muc-1 (10/63 vs. 1/14), spdef (7/58 vs. 0/25) and mgb1 (5/55 vs. 0/25). It is notable, that Zhong et al. (1999) ...
7
Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
... plasma circulating cell-free tumour DNA (ctDNA) is detectable at an early stage, the size of the tumour does not strongly correlate with concentration of whole cell-free DNA (cfDNA), ...
8
Biomarkers characterization of circulating tumour cells in breast cancer patients
... HER2 DNA Probe Kit from Abbott Molecular (Abbott Park, IL, USA) in two centers and PharmaDX from Dako in two centers - in accordance with current recommendations ...
12
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
... with DNA environmental damage, ...in DNA mismatch repair and DNA replication or in tumors characterized by micro- satellite instability, as in colorectal cancer [21, ...
13
Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
... CA-125 together with risk of malignancy index values (RMI) were used to construct receiver-operating charac- teristics (ROC) curve, as compared with cf-DNA testing. The area under the curve (AUC) was assessed, it ...
10